Curcumin Analogs Enhance Bioavailability for Stroke Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for gliomas and intracerebral hemorrhage have limited efficacy due to low systemic bioavailability of curcumin and the need for novel therapeutic approaches, as gliomas are aggressive and intracerebral hemorrhage is difficult to treat with existing methods.
Innovation Solution
Development of curcumin analogs with enhanced systemic bioavailability, which can be administered in various forms, including pharmaceutically acceptable salts, prodrugs, and compositions for parenteral, oral, or topical delivery, to target NFκB activity and reduce inflammation and cell proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If curcumin is administered orally for treating intracerebral hemorrhage, then anti-inflammatory and antioxidant effects are achieved, but systemic bioavailability remains low
Solution Approach 1:
The patent modifies the chemical structure of curcumin by changing parameters such as hydroxyl group positions, methoxyl group substitutions, and molecular weight to create analogs with improved pharmacokinetic properties including enhanced systemic bioavailability while retaining therapeutic activity against intracerebral hemorrhage
Solution Approach 2:
The patent develops composite curcumin analog structures combining different functional groups (hydroxyl, methoxyl, carboxyl) in specific arrangements to create molecules that simultaneously achieve high bioavailability, blood-brain barrier penetration, and potent anti-inflammatory effects
2Reliability
If curcumin is used to treat gliomas, then anti-proliferative effects are observed, but the aggressive nature of gliomas limits treatment efficacy
Solution Approach 1:
The patent optimizes curcumin analog parameters including molecular weight (300-500 Da), logP values (2-4), and specific functional group configurations to enhance penetration into glioma cells and improve anti-proliferative activity against aggressive tumor cells
Solution Approach 2:
The patent introduces specific functional groups at strategic positions on the curcumin backbone to create local chemical properties that selectively target glioma cells, enhancing apoptosis induction and inhibiting NFκB-mediated survival pathways in tumor cells while sparing normal cells
3Reliability
If NFκB activation occurs in intracerebral hemorrhage, then inflammatory mediators are upregulated, but this leads to increased blood-brain barrier permeability and vasogenic edema
Solution Approach 1:
The patent employs curcumin analogs that preemptively inhibit NFκB activation and downstream inflammatory mediator expression (TNF-α, IL-6, IL-1β) to prevent the cascade of events leading to blood-brain barrier disruption and vasogenic edema, rather than treating these effects after they occur
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The curcumin analogs demonstrate increased bioavailability and effectiveness in reducing glioma cell viability, inflammation, and hematoma size, improving neurological outcomes and providing a potential treatment for gliomas and intracerebral hemorrhage.
Implementation Method 1
The activation of the pro-inflammatory transcription factor, NFκB, increased the expression of inflammatory mediators... Curcumin... possesses anti-inflammatory and antioxidant properties, in part via a reduction in AP-1 and NFκB activity
Implementation Method 2
Curcumin... possesses anti-inflammatory and antioxidant properties
Data Source
AI summary
Disclosed herein are compounds, compositions and methods for preventing and treating diseases such as intracerebral hemorrhage, cancer, or conditions associated with damaged cells, activated lymphocytes, or microbial products. The disclosed compounds are curcumin analogs. The curcumin analogs possess anti-inflammatory and antioxidant properties, which in part, reduce AP-1 and NF-κB activity.